Abciximab – Wikipedia
from Wikipedia, L’Encilopedia Libera.
L’ Abciximab It is an anti -aggregating biological drug, a monoclonal antibody directed against the GPIIB/IIIia receptor of the platelets. It is used for the prevention of thrombotic events during coronary angioplasty interventions [first] .
It is produced by Janssen Pharmaceutics (Janssen Biologicals) [2] and distributed in Europe by Eli Lilly and Company [3] .
ABCIXIMAB is the binding fragment The antigen of a human-murin chimeric monoclonal antibody, which specifically binds glycoprotein IIB/IIIA [first] [3] .
The GP IIB/IIIA is a transmembrane protein receptor capable of tieing the circulating fibrinogen or the factor of Von Willebrand [4] ; For this reason, once exposed on the platelet membrane, it allows platelet aggregation. The binding of the anti -corpo to the GP IIB/IIIA takes place through steric dimensions or conformational change and instead leads to the inhibition of the platelet aggregation.
Abciximab finds an indication only as adjuvant therapy during the intervention of coronary angioplasty (PCI) with stent positioning, together with the administration of aspirin and heparin, for the prevention of any ischemic/infartual complications of thrombotic origin that may arise during the procedure [first] .
A further indication is the unstable angina that does not respond to conventional therapy, with an indication of PCI intervention.
Since the risk of bleeding increases, the therapy with Abciximab is contraindicated in case of active bleeding, recent trauma or surgery, previous cerebrovascular events, neoplasms or cerebral arterial malformations, brain aneurisms [first] .
The administration of Abciximab provides a bolus of 0.5 mg/kg for intravenous injection, later an infusion at 0.125 µg/kg/minute [first] .
The main side effects are bleeding (from the femoral access site, gastrointestinal, urinary), cerebral hemorrhage and stroke, trombocytopenia [first] .
- ^ a b c d It is f Scheda fda ( PDF ), are Accessdata.fda.gov . URL consulted on July 31, 2021 .
- ^ Abciximab mother ( PDF ), are ema.europa.eu . URL consulted on July 31, 2021 .
- ^ a b Reopro approval . are thepharmaletter.com . URL consulted on July 31, 2021 .
- ^ ( IN ) Morayma Reyes Gil MD, PhD, Overview of the Coagulation System , in Transfusion Medicine and Hemostasis , Elsevier, 2019, pp. 559-564, DOI: 10.1016/B978-0-12-813726-0.00091-X . URL consulted on July 31, 2021 .
- Abul K. Abbas, Andrew H. Lichtman e Shiv Pillai, Cell and molecular immunology , Elsevier srl, 2010, pp. 79–, ISBN 978-88-214-3176-0.
- Humphrey P. Rang, M. Maureen Dale e James M. Ritter, Pharmacology , Elsevier srl, 2008, pp. 778–, ISBN 978-88-214-3023-7.
- Enzo Fagiolo, Immunoematologia , Mediserve S.R.L., 2007, PP. 16–, ISBN 978-88-8204-135-9
- Paolo Larizza, Treaty of internal medicine , Picn, 2005, PP. 909–, ISBN 978-88-299-1721-1
- ( IN ) WHO-List Inn of Monoclonal Antibodies ( PDF ), are whqlibdoc.why.int .
- ( IN ) Marie A. Simmons, Monoclonal antibodies: new research , Nova Publishers, 2005, ISBN 978-1-59454-247-3.
- ( IN ) Zhiqiang an, Therapeutic Monoclonal Antibodies: From Bench to Clinic , John Wiley and Sons, 8 settembre 2009, ISBN 978-0-470-11791-0.
Abciximab [ change | Modifica Wikitesto ]
- Ferdinando M. Massari, Acute coronary syndrome, a new way of diagnosing, a new way of setting the therapy , Springer, 2005, pp. 61-, ISBN 978-88-470-0308-8.
- ( IN ) Peter J. Sharis, Christopher P. Cannon e Benjamin A. Steinberg, Evidence-Based Cardiology , Lippincott Williams & Wilkins, 1º Novembre 2010, pp. 291–, ISBN 978-0-7817-6473-5.
- ( IN ) F. Crea, Braunwald’s heart diseases. Treaty of cardiovascular medicine. With CD-ROM , Elsevier srl, 2007, pp. 1234–, ISBN 978-88-214-2987-3.
- ( IN ) Allen Jeremiah E David L. Brown, Cardiac Intensive Care , Elsevier Health Sciences, 12 dicember 2009, pp. 464–, ISBN 978-1-4160-3773-6
- ( IN ) Eric J. Topol, Textbook of interventional cardiology , Elsevier Health Sciences, 2003, pp. 1013–, ISBN 978-0-7216-9449-8.
Recent Comments